for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Denali Therapeutics Inc

DNLI.OQ

Latest Trade

28.41USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

12.39

 - 

30.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Denali Therapeutics Inc Reports Qtrly Net Loss Of $56.8 Mln

May 7 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES COVID-19 RESPONSE UPDATE.DENALI THERAPEUTICS INC - FOR THREE MONTHS ENDED MARCH 31, 2020, DENALI REPORTED A NET LOSS OF $56.8 MILLION.DENALI THERAPEUTICS INC - COLLABORATION REVENUE WAS $3.6 MILLION FOR THREE MONTHS ENDED MARCH 31, 2020.

Denali Therapeutics Says Paused Enrollment in Phase 1, Phase 1B Trials Due To Covid-19

April 2 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS PROVIDES PIPELINE AND BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC.DENALI THERAPEUTICS - FOR ONGOING DNL151 PHASE 1, PHASE 1B TRIALS, ENROLLMENT OF ADDITIONAL HEALTHY VOLUNTEERS & PATIENTS AT HIGHER DOSES HAS BEEN PAUSED DUE TO COVID-19.DENALI THERAPEUTICS - RECRUITMENT OF ADDITIONAL PATIENTS IN ETV:IDS PROGRAM FOR HUNTER SYNDROME HAS BEEN PAUSED DUE TO COVID-19 PANDEMIC.DENALI THERAPEUTICS INC - DNL310 PHASE 1/2 TRIAL IS ON TRACK TO COMMENCE IN Q2 2020.DENALI THERAPEUTICS - ENROLLMENT OF ADDITIONAL SUBJECTS IN EIF2B PROGRAM FOR ALS (DNL343 PHASE 1 TRIAL) HAS BEEN PAUSED DUE TO COVID-19 PANDEMIC.DENALI THERAPEUTICS - HAS DRUG SUPPLIES TO COMPLETE ONGOING TRIALS.DENALI THERAPEUTICS - ADDITIONAL DRUG SUBSTANCE SUPPLIES EXPECTED TO BE SUFFICIENT TO SUPPORT PLANNED CLINICAL TRIALS WELL INTO 2021.DENALI THERAPEUTICS - ON TRACK TO DECIDE ON NEXT STEPS WITH DNL747 BY MID-2020 TOGETHER WITH ITS PARTNER SANOFI.DENALI THERAPEUTICS - WITH CASH AND INVESTMENTS OF ABOUT $614 MILLION AT END OF FEB 2020, BUSINESS OPERATIONS EXPECTED TO BE FUNDED AT LEAST THROUGH 2022.

Denali Therapeutics Inc Posts Qtrly Loss Per Share Of $0.56

Feb 27 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.QTRLY LOSS PER SHARE $0.56.QTRLY COLLABORATION REVENUE $4.7 MILLION VERSUS $125.7 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.58 -- REFINITIV IBES DATA.

Denali Therapeutics Says Public Offering Of 7.83 Million Common Shares Priced At $23.00 Per Share

Jan 28 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.83 MILLION COMMON SHARES PRICED AT $23.00PER SHARE.

Denali Therapeutics Says Intends To Offer & Sell Shares In Underwritten Public Offering Of $150 Mln Of Shares Of Common Stock

Jan 27 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.DENALI THERAPEUTICS - INTENDS TO OFFER & SELL SHARES IN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF COMMON STOCK.

Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program For Parkinson's Disease

Jan 14 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS ANNOUNCES BROAD PIPELINE PROGRESS INCLUDING POSITIVE RESULTS FROM ITS LRRK2 PROGRAM FOR PARKINSON'S DISEASE.DENALI THERAPEUTICS INC - IND SUBMITTED FOR DNL310 FOR HUNTER SYNDROME.DENALI THERAPEUTICS INC - CTA APPROVED FOR DNL343.DENALI THERAPEUTICS INC - RIPK1 INHIBITOR DNL747 PHASE 1B TRIALS IN ALZHEIMER'S AND ALS FULLY ENROLLED.DENALI THERAPEUTICS -INTENDS TO SELECT DNL201 OR DNL151 IN MID-2020 TO ADVANCE INTO PHASE 2/3 CLINICAL TRIALS IN PATIENTS WITH PARKINSON'S DISEASE.

Denali Therapeutics Reports Third Quarter Loss Per Share Of $0.48

Nov 6 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.DENALI THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $502.9 MILLION AS OF SEPTEMBER 30, 2019.DENALI THERAPEUTICS INC QTRLY LOSS PER SHARE $0.48.

Denali Therapeutics Inc Reports Quarterly Loss Per Share Of $0.61

Aug 6 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $4.2 MILLION FOR 3 MONTHS ENDED JUNE 30, 2019, VERSUS COLLABORATION REVENUE OF $1.6 MILLION FOR 3 MONTHS ENDED JUNE 30, 2018.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $534.4 MILLION AS OF JUNE 30, 2019.QTRLY LOSS PER SHARE $0.61.Q2 EARNINGS PER SHARE VIEW $-0.46, REVENUE VIEW $3.9 MILLION -- REFINITIV IBES DATA.

Denali Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designation For Dnl310

June 11 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS RECEIVES ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATION FOR DNL310, AND EXPANDS ITS PORTFOLIO OF BRAIN PENETRANT ENZYME REPLACEMENT PROGRAMS.DENALI THERAPEUTICS INC - DNL310 ON TRACK TO ENTER PHASE 1/2 CLINICAL STUDY IN HUNTER SYNDROME PATIENTS IN 2020.DENALI THERAPEUTICS - BASED ON PRE-CLINICAL PROOF OF CONCEPT WITH DNL310, CO INITIATED TWO ADDITIONAL ERT PROGRAMS THAT ARE ENABLED BY TV TECHNOLOGY..

Denali Therapeutics Says Collaboration Revenue Was $4.2 Mln For Three Months Ended March 31, 2019

May 8 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $4.2 MILLION FOR 3 MONTHS ENDED MARCH 31, 2019, VERSUS $0.6 MILLION FOR 3 MONTHS ENDED MARCH 31, 2018.COLLABORATION REVENUE WAS $4.2 MILLION FOR THREE MONTHS ENDED MARCH 31, 2019.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $583.0 MILLION AS OF MARCH 31, 2019..QTRLY LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE VIEW $-0.46, REVENUE VIEW $3.9 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up